Allopurinol Benefits Left Ventricular Mass and Endothelial Dysfunction in Chronic Kidney Disease

Michelle P. Kao (Lead / Corresponding author), Donald S. Ang, Stephen J. Gandy, M. Adnan Nadir, J. Graeme Houston, Chim C. Lang, Allan D. Struthers

    Research output: Contribution to journalArticlepeer-review

    139 Citations (Scopus)

    Abstract

    Allopurinol ameliorates endothelial dysfunction and arterial stiffness among patients without chronic kidney disease (CKD), but it is unknown if it has similar effects among patients with CKD. Furthermore, because arterial stiffness increases left ventricular afterload, any allopurinol-induced improvement in arterial compliance might also regress left ventricular hypertrophy (LVH). We conducted a randomized, double-blind, placebo-controlled, parallel-group study in patients with stage 3 CKD and LVH. We randomly assigned 67 subjects to allopurinol at 300 mg/d or placebo for 9 months; 53 patients completed the study. We measured left ventricular mass index (LVMI) with cardiac magnetic resonance imaging (MRI), assessed endothelial function by flow-mediated dilation (FMD) of the brachial artery, and evaluated central arterial stiffness by pulse-wave analysis. Allopurinol significantly reduced LVH (P = 0.036), improved endothelial function (P = 0.009), and improved the central augmentation index (P = 0.015). This study demonstrates that allopurinol can regress left ventricular mass and improve endothelial function among patients with CKD. Because LVH and endothelial dysfunction associate with prognosis, these results call for further trials to examine whether allopurinol reduces cardiovascular events in patients with CKD and LVH.

    Original languageEnglish
    Pages (from-to)1382-1389
    Number of pages8
    JournalJournal of the American Society of Nephrology
    Volume22
    Issue number7
    DOIs
    Publication statusPublished - Jul 2011

    Keywords

    • XANTHINE-OXIDASE INHIBITION
    • STAGE RENAL-DISEASE
    • HEART-FAILURE
    • ESSENTIAL-HYPERTENSION
    • UREMIC CARDIOMYOPATHY
    • CARDIOVASCULAR EVENTS
    • FOLLOW-UP
    • HYPERTROPHY
    • HEMODIALYSIS
    • REGRESSION

    Cite this